Related Experiment Video
Updated: Feb 9, 2026

Reconstitution Of β-catenin Degradation In Xenopus Egg Extract
Published on: June 17, 2014
Histone methyltransferase SETD2 regulates osteosarcoma cell growth and chemosensitivity by suppressing Wnt/β-catenin
Chaoyin Jiang1, Chao He2, Zhiqiang Wu3
1Department of Bone Tumor Surgery, Changzheng Hospital, Second MilitaryMedical University, Shanghai, 200003, China.
Abstract:
SETD2 is a histone methyltransferase that catalyzes the trimethylation of lysine 36 on histone 3. SETD2 is frequently found to be mutated or deleted in a variety of human tumors, whereas the role of SETD2 in oncogenesis of osteosarcoma has never been defined. Here in our study, we uncovered that SETD2 regulates tumor growth and chemosensitivity of osteosarcoma. Overexpression of SETD2 significantly inhibited osteosarcoma cell growth in vitro and in vivo. Moreover, SETD2 significantly enhanced cisplatin-induced apoptosis in osteosarcoma cells and inhibited cancer stem cell properties in OS cells. SETD2 regulates Wnt/β-catenin signaling and its downstream gene c-myc, CD133 and cyclin D1. We further revealed that SETD2 upregulates H3K36me3 modification in GSK3B loci and promotes its transcription, which lead to β-catenin degradation. Together, our study delineates SETD2 function in osteosarcoma as an important regulator of Wnt/β-catenin signaling, and suggests SETD2 as a novel target in diagnosis and combined chemotherapy of osteosarcoma.
Insights
The study found that SETD2 (histone methyltransferase) inhibits osteosarcoma growth and enhances chemotherapy sensitivity. SETD2 regulates Wnt/β-catenin signaling, suggesting it as a potential diagnostic and therapeutic target for osteosarcoma.
Area of Science:
- Molecular Biology
- Oncology
- Epigenetics
Background:
- SETD2, a histone methyltransferase, catalyzes H3K36 trimethylation.
- SETD2 mutations are common in human cancers, but its role in osteosarcoma is undefined.
- Osteosarcoma (OS) is a primary bone cancer with limited treatment options.
Purpose of the Study:
- To investigate the role of SETD2 in osteosarcoma (OS) oncogenesis.
- To determine SETD2's impact on OS tumor growth and chemosensitivity.
- To elucidate the molecular mechanisms by which SETD2 influences OS.
Main Methods:
- In vitro and in vivo studies of osteosarcoma cell lines.
- Assessment of apoptosis, cell growth, and cancer stem cell properties.
- Analysis of Wnt/β-catenin signaling pathway components and downstream targets (c-myc, CD133, cyclin D1).
- Chromatin immunoprecipitation (ChIP) to examine H3K36me3 modification at GSK3B loci.
Main Results:
- SETD2 overexpression significantly inhibited osteosarcoma cell proliferation in vitro and in vivo.
- SETD2 enhanced cisplatin-induced apoptosis and suppressed cancer stem cell characteristics in OS cells.
- SETD2 was found to regulate Wnt/β-catenin signaling by upregulating H3K36me3 at GSK3B, promoting its transcription and leading to β-catenin degradation.
Conclusions:
- SETD2 acts as a tumor suppressor in osteosarcoma.
- SETD2 regulates osteosarcoma progression and chemosensitivity through the Wnt/β-catenin pathway.
- SETD2 represents a novel therapeutic target for osteosarcoma diagnosis and combination chemotherapy.
Related Concept Videos
Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
Canonical Wnt Signaling Pathway
Non-Canonical Wnt Signaling Pathways
Catenins
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the...
TGF - β Signaling Pathway
Histone Variants at the Centromere

